ECSP10010401A - Paramyxovirus eficaz como antitumoral - Google Patents

Paramyxovirus eficaz como antitumoral

Info

Publication number
ECSP10010401A
ECSP10010401A EC2010010401A ECSP10010401A ECSP10010401A EC SP10010401 A ECSP10010401 A EC SP10010401A EC 2010010401 A EC2010010401 A EC 2010010401A EC SP10010401 A ECSP10010401 A EC SP10010401A EC SP10010401 A ECSP10010401 A EC SP10010401A
Authority
EC
Ecuador
Prior art keywords
virus
paramyxovirus
kill
antitumoral
effective
Prior art date
Application number
EC2010010401A
Other languages
English (en)
Inventor
Rudolf Beier
Florian Puehler
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ECSP10010401A publication Critical patent/ECSP10010401A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen paramyxovirus del grupo APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, virus Mapuera y virus Fer-de-Lance, los cuales pueden ser usados para la producción de un medicamento para el tratamiento de tumores. El virus tiene una selectividad para matar células tumorales humanas pero no para matar células diferenciadas normales humanas o en proliferación normal humanas con la misma dosis. Por medio de ingeniería genética, el virus se puede modificar de modo tal que se agreguen o reemplacen uno o más genes por los genes homólogos de un paramyxovirus relacionado. Por ese método, la actividad antitumoral del virus quimérico resultante se potencia en comparación con el virus parental.
EC2010010401A 2008-02-14 2010-08-12 Paramyxovirus eficaz como antitumoral ECSP10010401A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075121 2008-02-14
US2965008P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
ECSP10010401A true ECSP10010401A (es) 2010-09-30

Family

ID=40955326

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010401A ECSP10010401A (es) 2008-02-14 2010-08-12 Paramyxovirus eficaz como antitumoral

Country Status (17)

Country Link
US (1) US20090208495A1 (es)
EP (1) EP2252307A2 (es)
JP (1) JP2011512344A (es)
KR (1) KR20100122482A (es)
CN (1) CN101945660A (es)
AU (1) AU2009214066A1 (es)
BR (1) BRPI0908365A2 (es)
CA (1) CA2715136A1 (es)
CO (1) CO6290694A2 (es)
CR (1) CR11631A (es)
DO (1) DOP2010000251A (es)
EA (1) EA201001266A1 (es)
EC (1) ECSP10010401A (es)
IL (1) IL206860A0 (es)
MX (1) MX2010008942A (es)
WO (1) WO2009101149A2 (es)
ZA (1) ZA201006561B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771540C (en) * 2009-08-21 2019-01-15 Merial Limited Recombinant avian paramyxovirus vaccine and method for making and using thereof
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
EP2579884B1 (en) 2010-06-10 2014-06-04 Intervet International B.V. Anti-tumor composition
AU2013212097B2 (en) * 2012-01-24 2017-01-12 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines
CN106163532B (zh) 2013-09-03 2019-12-31 免疫医疗有限公司 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP2021530501A (ja) * 2018-07-13 2021-11-11 アイカーン スクール オブ メディシン アット マウント サイナイ 癌の治療のためのａｐｍｖ及びその使用
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN115089591B (zh) * 2022-05-21 2024-04-12 复旦大学 布立尼布在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
CN116970650B (zh) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01010393A (es) * 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
AU7607900A (en) * 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
CN101875919A (zh) * 2004-11-12 2010-11-03 拜耳先灵医药股份有限公司 重组新城疫病毒

Also Published As

Publication number Publication date
IL206860A0 (en) 2010-12-30
WO2009101149A2 (en) 2009-08-20
WO2009101149A3 (en) 2009-11-05
CA2715136A1 (en) 2009-08-20
CO6290694A2 (es) 2011-06-20
ZA201006561B (en) 2012-02-29
CN101945660A (zh) 2011-01-12
EP2252307A2 (en) 2010-11-24
EA201001266A1 (ru) 2011-04-29
MX2010008942A (es) 2010-09-07
DOP2010000251A (es) 2010-08-31
BRPI0908365A2 (pt) 2015-08-11
CR11631A (es) 2010-10-05
KR20100122482A (ko) 2010-11-22
US20090208495A1 (en) 2009-08-20
AU2009214066A1 (en) 2009-08-20
JP2011512344A (ja) 2011-04-21

Similar Documents

Publication Publication Date Title
CO6290694A2 (es) Paramyxovirus eficaz como antitumoral
BR112017017810A2 (pt) materiais e métodos para tratamento de hemoglobinopatias
DOP2020000050A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CY1122275T1 (el) Μεσεγχυματικα στρωματικα κυτταρα και χρησεις που σχετιζονται με αυτα
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
MX2015007925A (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2020003965A (es) Terapias genicas para los trastornos lisosomales.
MY168762A (en) Certain chemical entities, compositions and methods
CU20140139A7 (es) Compuestos y composiciones para modular la actividad de egfr
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
EA201792092A1 (ru) Редактирование генов с использованием tat-индуцируемой crispr-эндонуклеазы
SG10201902574RA (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
CU20170145A7 (es) Métodos para tratar infecciones por el virus filoviridae
MX375431B (es) Virus de la enfermedad de newcastle y usos de los mismos.
EA201590888A1 (ru) Мутации флавивирусного белка оболочки, нарушающие разборку вириона
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
EA201391492A1 (ru) Соединения на основе микрорнк и способы модулирования активности mir-21
CR20120052A (es) Polipéptidos del factor ix modificados y usos de los mismos
PH12015502260A1 (en) C. novyi for the treatment of solid tumors in humans
MX2015012471A (es) Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
UY34773A (es) Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos